CO5261548A1 - Derivados de indol-3-ilo - Google Patents

Derivados de indol-3-ilo

Info

Publication number
CO5261548A1
CO5261548A1 CO01009901A CO01009901A CO5261548A1 CO 5261548 A1 CO5261548 A1 CO 5261548A1 CO 01009901 A CO01009901 A CO 01009901A CO 01009901 A CO01009901 A CO 01009901A CO 5261548 A1 CO5261548 A1 CO 5261548A1
Authority
CO
Colombia
Prior art keywords
het
atoms
nhr6
conh
hal
Prior art date
Application number
CO01009901A
Other languages
English (en)
Inventor
Mathias Wiesner
Simon Goodman
Rudolf Gottschlich
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CO5261548A1 publication Critical patent/CO5261548A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Derivados de indol-3-ilo de la formula I <EMI FILE="01009901_1" ID="1" IMF=JPEG >donde A y B independientemente entre sí significan O, S, NH, NR7, CO, CONH, NHCO o un enlace directo, X significa alquileno insustituido o monosustituido con R4 o R5 con 1 a 2 átomos de C o un enlace directo, R1 significa H, Z o -(CH2)o-Ar R2 significa H, R7 o -C(O)Z, R3 significa NHR6, -NR6-C(=NR6)-NHR6, -C(=NR6)-NHR6, -NR6-C(=NR9)NHR6 -C(=NR9)-NHR6 o-Het1, R4 o R5 independientemente entre sí significan H, oxo, R7 -(CH2)o-Ar, -C(O)-(CH2)o-Ar, -C(O)-(CH2)o-R7, -C(O)-(CH2)o-Het, Het, NHR6, MHAr, NH-Het, CONH-R7, CONH-(CH2)o-Ar, CONH-(CH2)o-Het, OR7, OAr, OR6 o O-Het, R6 significa H, -C(O)R7, -C(O)-Ar, -C(O)-Het, R7, COOR7, COO-(CH2)o -Ar, COO-(CH2)o-Het, SO2-Ar, SO2R7 o SO2-Het, R7 significa alquilo con 1 a 10 átomos de C o cicloalquilo con 3 a 10 átomos de C, R8 significa Hal, NO2, CN, Z, -(CH2)o-(CH2)o-Ar, COOR1, OR1, CF3, OCF3, SO2R1, NHR1, N-(R1)2, NH-C(O)R1, NHCOOR1, COOH, COOZ o C(O)R1, R9 significa CN o NO2, Z significa alquilo con 1 a 6 átomos de C, Ar significa arilo insustituido o sustituido una o varias veces con R8, Hal significa F, Cl, Br o I, Het significa un resto mono-o bicíclico saturado, parcial-o totalmente insaturado con 5 a 10 elementos del anillo, donde pueden estar presente 1 o 2 átomos de N y/o 1 o 2 átomos de S u O y el resto heterocíclico puede estar sustituido una o dos veces con R8, Het1 significa un resto mono-o bicíclico heterocíclico saturado, parcial-o totalmente insaturado con 5 a 10 elementos del anillo y 1 a 4 átomos de N, que puede estar insustituido una o dos veces con Hal, R7, OR7, CN, NHZ, oxo o NO2, n significa 0, 1 o 2, m significa 0, 1, 2, 3, 4, 5 o 6, 0 significa 0, 1 o 2, así como sus sales y solvatos fisiológicamente inofensivos.
CO01009901A 2000-02-11 2001-02-09 Derivados de indol-3-ilo CO5261548A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10006139A DE10006139A1 (de) 2000-02-11 2000-02-11 Indol-3-yl-Derivate

Publications (1)

Publication Number Publication Date
CO5261548A1 true CO5261548A1 (es) 2003-03-31

Family

ID=7630611

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01009901A CO5261548A1 (es) 2000-02-11 2001-02-09 Derivados de indol-3-ilo

Country Status (28)

Country Link
US (1) US6743810B2 (es)
EP (1) EP1254133B9 (es)
JP (1) JP4938194B2 (es)
KR (1) KR20020073585A (es)
CN (1) CN1214026C (es)
AR (1) AR027398A1 (es)
AT (1) ATE293620T1 (es)
AU (2) AU3166401A (es)
BR (1) BR0108154A (es)
CA (1) CA2399813C (es)
CO (1) CO5261548A1 (es)
CZ (1) CZ20022616A3 (es)
DE (2) DE10006139A1 (es)
EC (1) ECSP013923A (es)
ES (1) ES2240400T3 (es)
HK (1) HK1051863A1 (es)
HU (1) HUP0302671A2 (es)
IL (1) IL151154A0 (es)
MX (1) MXPA02007732A (es)
NO (1) NO20023770L (es)
NZ (1) NZ521260A (es)
PE (1) PE20011125A1 (es)
PL (1) PL356427A1 (es)
PT (1) PT1254133E (es)
RU (1) RU2257380C2 (es)
SK (1) SK11152002A3 (es)
WO (1) WO2001058893A2 (es)
ZA (1) ZA200207273B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063790A1 (en) * 1996-05-31 2004-04-01 The Scripps Research Institute Methods for inhibition of angiogenesis
US20040138284A1 (en) * 2000-02-11 2004-07-15 Matthias Wiesner Indol-3-yl derivatives
AU2001288485A1 (en) * 2000-08-29 2002-03-13 Balekudru Devadas Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
SK5902003A3 (en) 2000-11-01 2003-08-05 Merck Patent Gmbh Methods and compositions for the treatment of diseases of the eye
GB0028367D0 (en) * 2000-11-21 2001-01-03 Celltech Chiroscience Ltd Chemical compounds
JP4615826B2 (ja) 2001-01-29 2011-01-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換インドールおよびインテグリンアンタゴニストとしてのそれらの使用
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
WO2003013511A1 (en) 2001-08-01 2003-02-20 Merck Patent Gmbh Integrin inhibitors for the treatment of eye diseases
WO2003068253A1 (en) * 2002-02-14 2003-08-21 Merck Patent Gmbh Methods and compositions for the treatment of eye diseases
US20070208026A1 (en) * 2003-04-07 2007-09-06 Liu Kevin N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders
US7592361B2 (en) * 2003-04-28 2009-09-22 Bayer Pharmaceuticals Corporation Indole acetic acid derivatives and their use as pharmaceutical agents
US7211588B2 (en) 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
DE10337863A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Verwendung von Chromen-4-on-Derivaten
DK1667668T3 (da) * 2003-10-01 2008-09-15 Merck Patent Gmbh Alfabeta3 og altabeta6-integrinantagonister som antifibrotiske midler
EP1758856A2 (en) * 2004-05-04 2007-03-07 Novo Nordisk A/S Indole derivatives for the treatment of obesity
US8003806B2 (en) * 2004-11-12 2011-08-23 OSI Pharmaceuticals, LLC Integrin antagonists useful as anticancer agents
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
CN102335168B (zh) * 2011-10-25 2014-04-02 合肥博太医药生物技术发展有限公司 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗骨质疏松药物中的应用
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
KR102344105B1 (ko) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 모노시클릭 피리딘 유도체의 염 및 이의 결정
MX2020008610A (es) 2018-03-28 2020-09-21 Eisai R&D Man Co Ltd Agente terapeutico para carcinoma hepatocelular.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT290523B (de) * 1962-01-05 1971-06-11 Merck & Co Inc Verfahren zur Herstellung neuer α-(3-Indolyl)-carbonsäuren
GB1148909A (en) * 1965-04-19 1969-04-16 Sumitomo Chemical Co Process for production of novel phenylhydrazone and phenylhydrazine derivatives
US4824850A (en) * 1982-05-18 1989-04-25 University Of Florida Brain-specific drug delivery
US4983615A (en) * 1989-06-28 1991-01-08 Hoechst-Roussel Pharmaceuticals Inc. Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
IT1244548B (it) * 1991-02-06 1994-07-15 Poli Ind Chimica Spa Derivati della 5-oxo-l-prolina e loro applicazioni farmaceutiche
GB9225141D0 (en) * 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
JP2000508319A (ja) 1996-04-10 2000-07-04 メルク エンド カンパニー インコーポレーテッド αｖβ３拮抗薬
EP0923548B1 (en) * 1996-08-27 2003-03-12 Wyeth 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht 1a ligands
AU1687699A (en) * 1997-12-25 1999-07-19 Yamanouchi Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives
EA005244B1 (ru) * 1998-02-23 2004-12-30 Саут Алабама Медикал Сайенс Фаундейшн Индол-3-пропионовые кислоты, их соли и эфиры, используемые в качестве лекарств
ID26250A (id) * 1998-02-25 2000-12-07 Genetics Inst Inhibitor-inhibitor dari enzim-enzim fosfolipase
CA2327303A1 (en) * 1998-04-08 1999-10-14 American Home Products Corporation N-aryloxyethylamine derivatives for the treatment of depression
WO1999051575A1 (en) * 1998-04-08 1999-10-14 American Home Products Corporation N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
JP4425699B2 (ja) * 2004-05-17 2010-03-03 川崎重工業株式会社 小型滑走艇

Also Published As

Publication number Publication date
KR20020073585A (ko) 2002-09-27
SK11152002A3 (sk) 2003-01-09
ATE293620T1 (de) 2005-05-15
HUP0302671A2 (hu) 2003-12-29
CZ20022616A3 (cs) 2002-10-16
ZA200207273B (en) 2003-12-10
BR0108154A (pt) 2003-01-21
ECSP013923A (es) 2002-09-27
CA2399813C (en) 2010-03-09
DE50105955D1 (de) 2005-05-25
AU2001231664B2 (en) 2006-02-23
PL356427A1 (en) 2004-06-28
IL151154A0 (en) 2003-04-10
PT1254133E (pt) 2005-09-30
CN1398264A (zh) 2003-02-19
US20030045728A1 (en) 2003-03-06
AU3166401A (en) 2001-08-20
EP1254133B1 (de) 2005-04-20
ES2240400T3 (es) 2005-10-16
RU2002123332A (ru) 2004-01-10
DE10006139A1 (de) 2001-08-16
HK1051863A1 (en) 2003-08-22
AR027398A1 (es) 2003-03-26
WO2001058893A3 (de) 2002-04-18
AU2001231664C1 (en) 2006-10-05
WO2001058893A2 (de) 2001-08-16
JP2003530319A (ja) 2003-10-14
CN1214026C (zh) 2005-08-10
RU2257380C2 (ru) 2005-07-27
NO20023770D0 (no) 2002-08-09
EP1254133A2 (de) 2002-11-06
US6743810B2 (en) 2004-06-01
MXPA02007732A (es) 2002-10-11
CA2399813A1 (en) 2001-08-16
JP4938194B2 (ja) 2012-05-23
PE20011125A1 (es) 2001-11-07
EP1254133B9 (de) 2005-09-07
NO20023770L (no) 2002-08-09
NZ521260A (en) 2004-02-27

Similar Documents

Publication Publication Date Title
CO5261548A1 (es) Derivados de indol-3-ilo
CO5080778A1 (es) Inhibidores de enzimas
ES2184280T3 (es) Compuestos de indol como inhibidores de cox-2&#39;.
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
NO2016005I2 (no) Brivaracetam
CO4990956A1 (es) Derivados de tienopirimidina y de la tienopiridina utiles comoagentes anticancerigenos
CO4970733A1 (es) Tetrahidro prostaglandinas aromaticas c16-c20 sustituidas utiles como agonistas fp
CO4970731A1 (es) Tetrahidro prostaglandinas c16-c29 sustituidas utiles como agonistas fp
AR015269A1 (es) Compuesto amidinico y composicion farmaceutica, inhibidor de la coagulacion sanguinea e inhibidor del factor xa que lo comprenden
CL2007003822A1 (es) Compuestos derivados de isoquinolina e isoquinolinona, inhibidores de rho-quinasa; composicion farmaceutica; y uso para tratar y/o prevenir hipertension, retinopatia, glaucoma, fibrosis pulmonar, alzheimer, disfuncion erectil, trastornos tromboticos, entre otras.
CO5700725A2 (es) Derivados sustituidos de la ciclohexano-1,4-diamina
CO5680419A2 (es) Derivados de 1-[(indol-3-il)carbonil] piperazinas
ES2079576T3 (es) Derivados piranicos biciclicos y su uso como inhibidores de 5-lipoxigenasa.
PE20081557A1 (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
AR021135A1 (es) Moduladores del receptor de aminoacidos excitadores
UY25986A1 (es) Complejo del inhibidor de ras-farnesiltransferasa y sulfobutiléter-7-beta-ciclodextrina o 2-hidroxipropil-beta-ciclodextrina y método.
AR072046A1 (es) Derivados de urea heterociclicos y sus metodos de uso
AR042733A1 (es) Derivados de piridinas utilizados como inhibidores del mecanismo de intercambio na+/ca2+
HUP0002330A2 (hu) Azetidinilpropilpiperidin-származékok, ezek intermedierjei és tachikinin antagonistaként történő alkalmazásuk
AR029343A1 (es) USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN
AR039651A1 (es) Derivados de isoquinolina
ATE257834T1 (de) Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe
EA199800377A1 (ru) Антагонисты рецепторов возбудительной аминокислоты
AR025638A1 (es) Conjugados de glucopiranosidas de 2-(4-hidroxi-fenil)-3-metil-1-/4-(2-amin-1-il-etoxi)-bencil/-1h-indol-5-oles
DE60105028D1 (de) Ruthenium (ii) verbindungen in der krebsbehandlung

Legal Events

Date Code Title Description
FC Application refused